A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

NCT04176198 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelofibrosis

Interventions

DRUG: Nusivertib
DRUG: Ruxolitinib
DRUG: Momelotinib

Sponsor

Sumitomo Pharma America, Inc.